Clinical trial

MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)

NCT03552536

Study summary

ClinicalTrials.gov

MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention MK-8583 Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-10-07

PhasePHASE1

Conditions

HIV-1 Infectionunresolved

Interventions

MK-8583DRUG

Sponsors & collaborators

Merck Sharp & Dohme LLClead sponsor

Mapped research locations

BerlinGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03552536 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.